Relationship between metabolical associated steatotic liver disease and ischemic heart disease: clinical aspects of comorbidity
Abstract
Background. To investigate the association between metabolically associated steatotic liver disease (MASLD) and ischemic heart disease (IHD), focusing on the clinical aspects of their comorbidity.
Materials and methods. Data from 110 patients with IHD were analyzed. MASLD was diagnosed using liver ultrasound and metabolic parameters. Correlation and regression analyses were conducted to evaluate the relationship between metabolic disturbances and IHD severity.
Results. MASLD was identified in 77.3% of patients with IHD. The severity of liver steatosis correlated with C-reactive protein levels, HOMA-IR index, and the frequency of acute coronary events. Patients with severe steatosis were more likely to experience myocardial infarction and dyslipidemia.
Conclusion. MASLD is a significant risk factor that exacerbates the course of IHD. Early diagnosis and correction of metabolic disorders are essential for improving the prognosis of patients with this comorbidity.
About the Authors
List of references
Chalasani N., Younossi Z., Lavine J.E., The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guidance, Hepatology, 2018, 67, 01, 328–357
Chan W., Chuah K., Rajaram R., Lim L., Ratnasingam J., Vethakkan S., Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review, Journal of Obesity and Metabolic Syndrome, 2023, 10.7570/jomes23052
De Groot J.M., Santos S., Geurtsen M.L., Felix J.F., Jaddoe V., Risk Factors and Cardio-Metabolic Outcomes Associated with Metabolic-Associated Fatty Liver Disease in Childhood, EClinicalMedicine, 2023, 65, 102248, 10.1016/j.eclinm.2023.102248.
Lim L., Chow E., Chan J.C.N., Cardiorenal Diseases in Type 2 Diabetes Mellitus: Clinical Trials and Real-World Practice, Nature Reviews Endocrinology, 2022, 10.1038/s41574-022-00776-2.
Ng C., Huang D.Q., Nguyen M., NAFLD versus MAFLD: Prevalence, Outcomes and Implications of a Change in Name, Clinical and Molecular Hepatology, 2022, 10.3350/cmh.2022.0070.
Pan Z., Shiha G., Esmat G., Me´ndez-Sa´nchez N., Eslam M., MAFLD Predicts Cardiovascular Disease Risk Better than MASLD, Liver International, 2024, 44, 10.1111/liv.15931.
Targher G., Byrne C.D., Tilg H., MASLD: A Systemic Metabolic Disorder with Cardiovascular and Malignant Complications, Gut, 2024, 73, 10.1136/gutjnl-2023-330595.
Zhou X., Targher G., Byrne C., Somers V., Kim S., Chahal C. A., Wong V., Cai J., Shapiro M., Eslam M., Steg P., Sung K., Misra A., Li J., Brotons C., Huang Y., Papatheodoridis G., Sun A., Yılmaz Y., Chan W., An International Multidisciplinary Consensus Statement on MAFLD and the Risk of CVD, Hepatology International, 2023, 10.1007/s12072-023-10543-8.
Ivanov I.I., Petrov P.P., Metabolic Disorders in Comorbid Conditions, Publishing House of Medical Literature, , 2020, 320, In Russian: Иванов И.И.; Петров П.П. Метаболические нарушения при коморбидных состояниях. Изд-во медицинской литературы: Москва, 2020; 320 с.
Makhkamova M.M., Nurillaeva N.M., Study of the Frequency of Compliance with the Criteria of Metabolic Dysfunction in Patients with Ischemic Heart Disease and Associated Hematological Profile Disorders, Journal of Humanities and Natural Sciences, 2024, 1, 015, 166–168, https://journals.tnmu.uz/index.php/ gtfj/article/view/732, Accessed: 23.01.2025. In Russian: Махкамова М.М.; Нуриллаева Н.М. Изучение частоты соответствия критериям метаболической дисфункции у больных с ишемической болезнью сердца и сопутствующими нарушениями гематологического профиля. Журнал гуманитарных и естественных наук 2024, 1 (15), 166–168.
Medvedev V.M., Tikhonova A.S., Solovyov A.V., Metabolic Dysfunction in Ischemic Heart Disease: Relationship with Inflammation and Lipid Metabolism, Medical News, 2022, 31, 08, 45–51, In Russian: Медведев В.М.; Тихонова А.С.; Соловьев А.В. Метаболическая дисфункция при ИБС: Связь с воспалением и липидным обменом. Медицинские новости 2022, 31 (8), 45–51.
Ministry of Health of the Russian Federation, Report on the Treatment of Cardiovascular Diseases, Moscow, 2023, 45, In Russian: Министерство здравоохранения Российской Федерации. Отчет по лечению сердечно-сосудистых заболеваний. Москва, 2023; 45 с.
Petrov N.N., Sidorova E.V., Mikhailov S.S., The Role of Insulin Resistance in the Pathogenesis of Ischemic Heart Disease, Cardiology and Metabolism, 2021, 59, 07, 112–117, In Russian: Петров Н.Н.; Сидорова Е.В.; Михайлов С.С. Роль инсулинорезистентности в патогенезе ишемической болезни сердца. Кардиология и метаболизм 2021, 59 (7), 112–117.
Sidorov A.A., Kuznetsova E.V., The Impact of Metabolic Syndrome on Cardiovascular Risks, Cardiology, 2021, 61, 05, 15–22, In Russian: Сидоров А.А.; Кузнецова Е.В. Влияние метаболического синдрома на сердечно-сосудистые риски. Кардиология 2021, 61 (5), 15–22.
Sidorov A.N., Belyaeva T.V., The Role of C-Reactive Protein in Predicting Cardiovascular Complications, International Medical Journal, 2021, 49, 010, 33–39, In Russian: Сидоров А.Н.; Беляева Т.В. Роль С-реактивного белка в прогнозировании сердечно-сосудистых осложнений. Международный меди- цинский журнал 2021, 49 (10), 33–39.
Yusupova O.K., Orlov E.V., Vasiliev P.N., Correction of Metabolic Disorders in Patients with Comorbidity of MASLD and Ischemic Heart Disease, Practical Medicine, 2023, 17, 06, 78–84, In Russian: Юс- упова О.К.; Орлов Е.В.; Васильев П.Н. Коррекция метаболических нарушений у пациентов с коморбидностью МАСБП и ИБС. Практическая медицина 2023, 17 (6), 78–84.
World Health Organization, Cardiovascular Diseases [Electronic resource], 2025, https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases, Accessed: 23.01.2025. In Russian: Всемирная организация здравоохранения. Сердечно-сосудистые заболевания [Электрон- ный ресурс]. URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases (дата обращения: 23.01.2025).
Copyright (c) 2025 М.М. Махкамова , Н.М. Нуриллаева (Автор)
This work is licensed under a Creative Commons Attribution 4.0 International License.